Since the European Commission granted marketing authorisation to Lazcluze® (lazertinib) in January 2025, interest in its chemistry has grown steadily across Europe. For API developers, CDMOs and generic R&D teams, the first sourcing decision is always the same: which Lazertinib key starting materials to qualify, and from whom. This guide explains the three building blocks behind the published lazertinib route and what European buyers should check before placing an order.
Why Lazertinib Key Starting Materials Matter for European Buyers
Lazertinib is a third-generation, mutant-selective EGFR tyrosine kinase inhibitor. In the EU it is used together with amivantamab as a first-line treatment for adults with advanced non-small cell lung cancer carrying EGFR exon 19 deletions or the exon 21 L858R mutation, as described in the EMA product information for Lazcluze.
Under ICH Q11, the point where GMP controls begin is defined by the starting materials declared in the dossier. Well-characterised Lazertinib key starting materials with a consistent impurity profile make that justification easier, reduce questions from EMA or national assessors, and protect downstream yield. A poor supplier choice at this stage is expensive to reverse later.
How Lazertinib Is Built: A Convergent Route
The gram-scale route disclosed by Yuhan (US20200207750A1) and reviewed in RSC Medicinal Chemistry is convergent. Two fragments are prepared in parallel and then joined:
- Pyrimidine–pyrazole fragment: an SNAr coupling of 3-phenyl-1H-pyrazole-4-carbaldehyde with 4-chloro-2-(methylthio)pyrimidine, followed by oxidation of the S-methyl group to an activated sulfone.
- Aniline fragment: an SNAr reaction between 4-fluoro-2-methoxy-5-nitroaniline and morpholine, followed by several steps that build the aniline coupling partner.
- Final assembly: the two fragments are coupled, then the dimethylaminomethyl side chain and the acrylamide warhead that binds covalently to EGFR are introduced.
The 3 Lazertinib Key Starting Materials We Supply
1. 3-Phenyl-1H-Pyrazole-4-Carbaldehyde (CAS 26033-20-5)
This pyrazole aldehyde carries the phenyl ring and the formyl handle that later becomes the dimethylaminomethyl side chain of lazertinib. Published structure–activity work shows that this phenyl-plus-amine pattern on the pyrazole is central to the drug’s potency and selectivity for mutant EGFR. Buyers usually focus on assay, regio-isomer content and aldehyde oxidation products. View 3-Phenyl-1H-Pyrazole-4-Carbaldehyde details.
2. 4-Chloro-2-(Methylthio)Pyrimidine (CAS 49844-90-8)
This activated chloropyrimidine forms the aminopyrimidine core that lazertinib shares with other third-generation EGFR inhibitors. The 4-chloro position reacts with the pyrazole nitrogen, while the 2-methylthio group is later oxidised to a sulfone that acts as the leaving group for coupling with the aniline fragment. Low moisture and tight control of hydrolysed or over-chlorinated pyrimidines keep this step clean. View 4-Chloro-2-(Methylthio)Pyrimidine details.
3. 4-Fluoro-2-Methoxy-5-Nitroaniline (CAS 1075705-01-9)
This fluorinated nitroaniline supplies the methoxy-aniline ring of lazertinib. Its activated fluorine is displaced by morpholine, and the nitro group is eventually reduced to the amine that carries the acrylamide warhead. The same compound is also a well-known osimertinib intermediate, so one qualified source can support more than one EGFR TKI programme. Positional isomers and residual nitration by-products are the main quality points. View 4-Fluoro-2-Methoxy-5-Nitroaniline details.
Lazertinib Key Starting Materials: Quick Reference Table
| Product | CAS No. | Role in the Lazertinib Route |
|---|---|---|
| 3-Phenyl-1H-Pyrazole-4-Carbaldehyde | 26033-20-5 | Pyrazole unit and side-chain handle |
| 4-Chloro-2-(Methylthio)Pyrimidine | 49844-90-8 | Central aminopyrimidine core |
| 4-Fluoro-2-Methoxy-5-Nitroaniline | 1075705-01-9 | Methoxy-aniline ring with morpholine |
What to Check Before Qualifying a Supplier
Before approving any supplier of Lazertinib key starting materials, European quality teams typically review the following points:
- Documentation: a CoA with HPLC purity and identity data, an SDS, and a route-of-synthesis summary to support your KSM justification.
- Impurity transparency: clear data on isomers, residual solvents and potentially mutagenic impurities in line with ICH M7.
- Batch consistency: results from several batches, not just a single sample.
- Scale-up readiness: the ability to move from gram samples to kilogram lots without changing the route.
- REACH and logistics: for EU imports, agree early how REACH obligations will be handled and confirm packaging suits your site.
Why Source Lazertinib Key Starting Materials from Lifechem Pharma
Lifechem Pharma has manufactured specialty chemicals and advanced intermediates in India since 2015. Our operations are certified to ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018, and our QC laboratory uses HPLC, GC-HS, FTIR and UV spectrophotometry to release every batch. Our team has met European partners at CPHI Frankfurt, so we understand the documentation that EU and UK teams expect.
For a wider view of our portfolio, read our Lazertinib intermediate manufacturer and supplier guide, or contact our team for samples, pricing and technical documents.
Frequently Asked Questions
What are the key starting materials for lazertinib?
In the published convergent route, the main building blocks are 3-phenyl-1H-pyrazole-4-carbaldehyde, 4-chloro-2-(methylthio)pyrimidine and 4-fluoro-2-methoxy-5-nitroaniline. The final KSM designation depends on each manufacturer’s own route and regulatory strategy.
Is 4-fluoro-2-methoxy-5-nitroaniline used only for lazertinib?
No. It is also a widely used intermediate in osimertinib synthesis, which makes it a useful material for teams working on several EGFR inhibitors.
Do you supply samples to Europe and the UK?
Yes. Share your required quantity and specification, and our team will confirm lead time, packaging and documentation for delivery to your site.
Conclusion
Reliable Lazertinib key starting materials are the foundation of a robust API process and a smoother European filing. With all three building blocks available from one ISO-certified source, Lifechem Pharma helps European and UK developers reduce supply risk from the first gram to commercial scale. Request a quote today.
Recent Comments